NAD+ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-12. Numbers and descriptions here follow the published literature rather than marketing material.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
=== Toxicity === Today nicotine is less commonly used in agricultural insecticides, which was a main source of poisoning. More recent cases of poisoning typically appear to be in the form of Green Tobacco Sickness (GTS), accidental ingestion of tobacco or tobacco products, or ingestion of nicotine-containing plants. People who harvest or cultivate tobacco may experience GTS, a type of nicotine poisoning caused by dermal exposure to wet tobacco leaves. This occurs most commonly in young, inexperienced tobacco harvesters who do not consume tobacco. People can be exposed to nicotine in the workplace by breathing it in, skin absorption, swallowing it, or eye contact. The Occupational Safety and Health Administration (OSHA) has set the legal limit (permissible exposure limit) for nicotine exposure in the workplace as 0.5 mg/m3 skin exposure over an 8-hour workday. The US National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) of 0.5 mg/m3 skin exposure over an 8-hour workday. At environmental levels of 5 mg/m3, nicotine is immediately dangerous to life and health.
==== Accidental myiasis ==== Accidental myiasis, also called pseudomyiasis, occurs when fly larvae are ingested or deposited on the body, leading to an infestation. It is caused by flies that have no preference or need to develop in a host but may do so on rare occasions. Transmission occurs through accidental deposit of eggs on oral or genitourinary openings, or by swallowing eggs or larvae that are on food. Enteric pseudomyiasis can cause nausea, vomiting and gastrointestinal upset. The cheese fly (Piophila casei) sometimes causes myiasis through intentional consumption of its maggots (which are contained in the traditional Sardinian delicacy casu marzu). Other flies that can accidentally cause myiasis are:
=== Books === Hocking, A. D.; Pitt, J. I.; Samson, Robert A.; Thrane, U., eds. (2006). Advances in Food Mycology. Advances in Experimental Medicine and Biology. Vol. 571. doi:10.1007/0-387-28391-9. ISBN 978-0-387-28385-2. McLauchlin, Jim; Little, Christine; Hobbs, Betty C. (2007). Hobbs' Food Poisoning and Food Hygiene. CRC Press. doi:10.1201/b13378. ISBN 978-1-4441-1374-7. Glass, Kathleen; Marshall, Kristin (2013). "Clostridium botulinum". Foodborne Infections and Intoxications. pp. 371–387. doi:10.1016/B978-0-12-416041-5.00027-5. ISBN 978-0-12-416041-5. Smith JL (2005). Fratamico PM, Bhunia AK, Smith JL (eds.). Foodborne Pathogens: Microbiology And Molecular Biology. Horizon Scientific Press. ISBN 978-1-904455-00-4.
Sources: en.wikipedia.org
=== Lily Tao === Lily Tao (played by an uncredited child actress in series 1, Neve Bonner in series 2-3, and Serrana Su-Ling Bliss in series 4) is one of Eric and Candice's daughters, alongside her twin sister Lara. In series 1, Harper spots Eric playing with his daughters in a grocery store after being suspended from Pierpoint. In series 2, Eric returns home from a trip to New York to kiss his children goodnight, having secretly cheated on their mother with his ex-girlfriend Holly during the trip. In series 3, Eric, divorced from Candice, brings his daughters to Pierpoint on the day of the tumultuous IPO of green-energy company Lumi. In series 4, Lily is older and attending private school in England, while Eric is retired and living in the United States, estranged from his family. His family office, LilyLara, is named after his daughters. Eric returns to London to partner with Harper on a short-only hedge fund, SternTao, and allows Lily to visit the hotel serving as their office, blurring the work-life boundary Harper strives to maintain with Eric. Eric later learns Lily has been expelled from school for running a catfishing scheme on another student, and reflects on how his daughter has inherited his own cruelty, while lamenting his own inability to properly love his children. He comforts Lily and allows her and Candice to stay in his suite, but visits a prostitute that same night.
Benign acute childhood myositis (BACM) is a syndrome characterized by muscle weakness and pain in the lower limbs that develop in children after a recent viral illness. It is transient with a spontaneous clinical resolution within 1 week.
== External links == Official website Duncan Sheik at the Internet Broadway Database Duncan Sheik at IMDb Duncan Sheik at Rounder Records Duncan Sheik discography at Discogs Duncan Sheik at International Songwriters Association
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.